Stock Track | CanSinoBIO Soars 5.18% on Positive Regulatory Update for Meningococcal Vaccine

Stock Track
2024-11-27

Shares of CanSinoBIO jumped 5.18% in Wednesday's trading session, outperforming the broader market, following a positive regulatory update on its meningococcal vaccine candidate Menhycia.

China's National Medical Products Administration has accepted the company's supplemental application to expand the approved age range for Menhycia from 3 months to 3 years old to 3 months to 6 years old. The vaccine, which is the first MCV4 vaccine product in China, is designed to protect against meningococcal diseases caused by serogroups A, C, Y, and W-135.

The positive regulatory development for Menhycia, a key pipeline asset for CanSinoBIO, has been welcomed by investors as it potentially expands the addressable market for the vaccine in China. The stock's surge reflects the market's optimism about the company's prospects and growth potential in the domestic vaccine market.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10